Spero Therapeutics receives SEC Wells Notice; CEO placed on paid administrative leave

Spero Therapeutics, Inc.

SEC staff preliminarily recommends enforcement action over 2022 disclosures on tebipenem HBr commercialization.
CEO Satyavrat Shukla agrees to paid administrative leave; CFO Esther Rajavelu appointed interim CEO.
Director Frank Thomas replaces Dr. Ankit Mahadevia as Chairman of the Board.
Preliminary cash and equivalents of $52.9M as of Dec 31, 2024; runway into mid-2026.
Phase 3 PIVOT-PO trial enrollment exceeds 60%; on track for full enrollment in 2H 2025.

item 2.02 item 5.02 item 8.01 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.